Table 2.
Oral agents |
Injectable |
Subdermal implant |
||||
---|---|---|---|---|---|---|
N | % | n | % | n | % | |
Visit frequency | ||||||
Every 3 months | 10 | 68.8 | 6 | 46.2 | 5 | 38.5 |
Every 6 months | 2 | 12.5 | 4 | 30.8 | 6 | 46.2 |
Annually | 0 | 0.0 | 0 | 0.0 | 2 | 15.4 |
Other | 1 | 7.7 | 3 | 23.1 | 0 | 0.0 |
HIV testing frequency | ||||||
Every 3 months | 11 | 84.6 | 8 | 61.5 | 6 | 46.2 |
Every 6 months | 1 | 7.7 | 3 | 23.1 | 6 | 46.2 |
Annually | 1 | 7.7 | 0 | 0.0 | 1 | 7.7 |
Other | 0 | 0.0 | 2 | 15.4 | 0 | 0.0 |
HIV testing—men who have sex with men | ||||||
Every 3 months | 12 | 92.3 | 9 | 69.2 | 11 | 84.6 |
Every 6 months | 1 | 7.7 | 1 | 7.7 | 2 | 15.4 |
Annually | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Other | 0 | 0.0 | 3 | 23.1 | 0 | 0.0 |
HIV testing—women who have sex with men | ||||||
Every 3 months | 9 | 69.2 | 7 | 53.8 | 8 | 81.5 |
Every 6 months | 4 | 30.8 | 4 | 30.8 | 5 | 38.5 |
Annually | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Other | 0 | 0.0 | 2 | 15.4 | 0 | 0.0 |
Renal function testing | ||||||
Every 3 months | 4 | 30.8 | 2 | 15.4 | 2 | 15.4 |
Every 6 months | 8 | 61.5 | 10 | 76.9 | 9 | 69.2 |
Annually | 1 | 7.7 | 1 | 7.7 | 2 | 15.4 |
Treatment barriers | ||||||
Limited insurance coverage | 11 | 84.6 | 12 | 92.3 | 13 | 100 |
High medication cost | 9 | 69.2 | 10 | 76.9 | 10 | 76.9 |
Patient adherence | 10 | 76.9 | 9 | 69.2 | 7 | 53.8 |
Limited pharmacy access to medication | 6 | 46.2 | 5 | 38.5 | 5 | 38.5 |
Consistent management across physicians | 5 | 38.5 | 6 | 46.2 | 5 | 38.5 |
Side effects | 3 | 23.1 | 4 | 30.8 | 6 | 46.2 |
Adverse reactions | 1 | 7.7 | 2 | 15.4 | 2 | 15.4 |